To assess safety and efficacy of ONYX treatment for cAVM:
The main objective of this study is to assess the safety at 1 month after any embolization session and the efficacy at: * 12 months post last embolization in case of treatment with embolization only * 12 months after additional treatment with neurosurgery * 36 months after additional treatment with radiosurgery
Study Type
OBSERVATIONAL
Enrollment
140
CHU Besançon
Besançon, France
Chu Pellegrin
Bordeaux, France
CHU Côte de Nacre
Caen, France
Incidence of Device or procedure Adverse Events
Device or procedure related adverse events
Time frame: 1 month
Healing rate
No residual early venous return * 12 months after last embolization in case of complete treatment or stopping treatment; * 12 months after additional intervention in case of additional treatment required by neuro-surgery; * 36 months after additional intervention in case of additional treatment required by radio-surgery.
Time frame: 12 or 36 months
Describe funtional independence
Describe mRS scores assessed by a certified physician
Time frame: 1 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU Gabriel Montpied
Clermont-Ferrand, France
CHI Dijon
Dijon, France
CHP Clairval
Marseille, France
Hôpital GUI DE CHAULLAC
Montpellier, France
CHU Nantes
Nantes, France
Fondation Ophtamoligique Rothschild
Paris, France
Groupe Hospitalier Pitier Salpetrière
Paris, France
...and 7 more locations